Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Investors: Take Advantage of Double Fed Tax Credits on Critical Minerals Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News bluebird bio Inc BLUE

Healthcare Biotechnology
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:BLUE)

bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

Business Wire November 7, 2023

bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

Business Wire November 2, 2023

bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million

Business Wire October 30, 2023

bluebird bio to Host Third Quarter 2023 Financial Results Conference Call

Business Wire October 24, 2023

bluebird bio Announces September Investor Events

Business Wire September 5, 2023

bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease

Business Wire August 16, 2023

bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress

Business Wire August 8, 2023

bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update

Business Wire July 25, 2023

bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events

Business Wire June 21, 2023
View More News ››

Opinion & Analysis (NDAQ:BLUE)

Coverage Initiated on Cancer Vaccine Firm

Streetwise Reports March 11, 2019

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors

Streetwise Reports April 25, 2018

Partnerships propel Stellar Biotechnologies' vaccine technology

The Life Sciences Report June 22, 2016

CAR T-cell therapeutics: Alan Leong of BioWatch looks beyond the buzz for solid early-stage plays

Gail Dutton September 10, 2015

Buy biotech when there's blood on the street: Pontifax's Ran Nussbaum

George S. Mack September 3, 2015

Zacks' Jason Napodano is not focused on a biotech bubble

George S. Mack July 9, 2015
View More Opinion ››

Bullboard Posts (NDAQ:BLUE)

RE:TD WATERHOUSE TOP 10 IN BIOTECHNOLOGY STOCKS

They should add EDT and SQD to their list .... like around the top. IMHO
inspecthrgadget - July 9, 2020

TD WATERHOUSE TOP 10 IN BIOTECHNOLOGY STOCKS

TD WATERHOUSE TOP 10 IN BIOTECHNOLOGY STOCKS Top 10 : 1.TRIL 2. BU 3. IBT 4. MDNA 5. APS 6. GENX 7. BLU 8. MBX 9. ARCH 10. MIR
TheBearInTheWoods - May 9, 2020

RE:RE:Amazing cure for bladder / brain cancer with laser tech

GRAMPS1996 - August 27, 2018

RE:Amazing cure for bladder / brain cancer with laser tech

An interesting Canadian company brother love. Difficult finding info. Found some news on yahoo.  Will keep an eye on it. 
norjase - August 27, 2018

Amazing cure for bladder / brain cancer with laser tech

I own many shares in Blue Bird Bio.  Similar company, which I must admit, appears to be developing better brain and bladder cancer...
Brotherlove - August 26, 2018

This stock sure looks like a Buy now to Target $120.00

 Complicated but do some research. This stock is at a value-inflection point and one can see a "slew of...
aebestacey - January 10, 2017
View more Bullboard ››

Torr Metals Inc.

Torr Metals Inc.

Torr Metals Inc, formerly Duro Metals Inc is a capital pool company. The principal business of the company is the ...
View More »